Rock Point Advisors LLC raised its stake in shares of LivaNova PLC (NASDAQ:LIVN – Free Report) by 34.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 78,475 shares of the company’s stock after buying an additional 19,940 shares during the quarter. Rock Point Advisors LLC’s holdings in LivaNova were worth $4,829,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. Arizona State Retirement System raised its stake in LivaNova by 1.7% during the third quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock valued at $845,000 after buying an additional 274 shares during the last quarter. Bayforest Capital Ltd raised its stake in shares of LivaNova by 44.8% in the third quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after purchasing an additional 284 shares during the last quarter. UMB Bank n.a. raised its stake in shares of LivaNova by 63.0% in the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after purchasing an additional 306 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of LivaNova by 0.9% in the second quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after purchasing an additional 458 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of LivaNova by 31.9% in the third quarter. PNC Financial Services Group Inc. now owns 1,901 shares of the company’s stock worth $100,000 after purchasing an additional 460 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on LIVN. Barclays boosted their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Piper Sandler restated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Stifel Nicolaus set a $80.00 price target on LivaNova in a research note on Wednesday, February 25th. Robert W. Baird decreased their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and an average price target of $77.22.
LivaNova Stock Performance
NASDAQ:LIVN opened at $71.75 on Wednesday. The stock has a 50-day simple moving average of $64.04 and a two-hundred day simple moving average of $62.50. LivaNova PLC has a 52-week low of $41.01 and a 52-week high of $72.78. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The firm has a market capitalization of $3.94 billion, a PE ratio of 36.79 and a beta of 0.82.
LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts forecast that LivaNova PLC will post 3.68 EPS for the current year.
LivaNova Profile
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Featured Articles
- Five stocks we like better than LivaNova
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN – Free Report).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
